Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 16th 2014

Biomarkers Could Determine Treatment for Esophageal Cancer

Research presented at the 56th Annual Meeting of the American Society for Radiation Oncology identified VEGF-A and TGF-beta as markers of treatment decision in patients with esophageal squamous cell carcinoma.

September 16th 2014

Alpelisib Provides Promise in Treating Cetuximab-Resistant Head and Neck Cancers

The results of a phase 1b study, presented at the AACR special conference "Targeting the PI3K-mTOR Network in Cancer," found that Alpelisib could overcome resistance to the anti-EGFR antibody cetuximab, and the two regimens together were quite beneficial.

September 15th 2014

In The Literature: MicroRNA Biomarkers Could Predict Chemotherapy Response in Lung Cancer

MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.

September 15th 2014

ASTRO Releases Additional Queries As a Part of the Choosing Wisely Initiative

This recommendation follows the list of 5 released last year by the organization, with the aim of helping the patient and physician choose appropriate treatments.

September 15th 2014

Counterfeit MabThera Found in Germany

Following Herceptin earlier this year, Roche has announced that tampered vials of it's blood cancer drug MabThera (Rituxan) were found in Germany.

September 15th 2014

Payers Restrict Coverage for Proton Radiation Therapy

Weighing the cost-benefit ratio of proton radiation therapy, private and public payers are placing coverage limitations on the use of this treatment.

September 15th 2014

To Treat or Not to Treat: The Overdiagnosis Debate

Rapid advances in detection technology, coupled with an increased awareness about screening, have ignited a debate on overdiagnosis and overtreatment of precancerous lesions. Should physicians use their discretion and implement a "wait-and-watch" approach?

September 12th 2014

Merck Serono to Halt Stage III NSCLC Trial With Tecemotide

Tecemotide, a synthetic lipopeptide immunotherapy was being developed as a cancer vaccine against the MUC1 glycoprotein that is often aberrantly overexpressed in NSCLC.

September 12th 2014

CMS's Open Payments Database on Schedule for Launch

Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.

September 11th 2014

In The Literature: MicroRNAs As Markers of Cancer Risk, Based on Ethnicity

The study, published in BMC Medical Genomics, identified ethnicity-based variability in microRNA expression that could lead to health disparities in cancer across the globe.

September 11th 2014

Study Evaluating Clinical Trial Bias in Pharma Presents Encouraging Evidence

The study, which evaluated the top 20 pharmaceutical companies, identified Amgen, AstraZeneca, and Celgene as the most dedicated to clinical trial data sharing.

September 11th 2014

NanoString Announces New PanCancer Immune Panel

The panel, developed in collaboration with immunooncology scientists around the world, including at INSERM, will help researchers create a profile of the human immune response in all cancer types.

September 11th 2014

Extended Use of Xtandi in Chemothrerapy-NaÃ¯ve Prostate Cancer Patients

The FDA approval will greatly influence the reach of the drug which was approved for use in advanced prostate cancer patients.

September 10th 2014

Watchful Waiting in Prostate Cancer: Role of Ethnicity

The retrospective study, conducted at the Thomas Jefferson University in Philadelphia, found that watchful waiting among black men with early stage prostate cancer who had undergone surgery, resulted in a more aggressive disease.

September 9th 2014

Androgen-Deprivation is Essential in Prostate Cancer Regimen

A joint statement by ASCO and CCO published new guidelines in the treatment of metastatic CRPC.

September 9th 2014

NICE Rejects Abraxane for Pancreatic Cancer

NICE does not deem Abraxane more effective than FOLFIRINOX, in addition to the fact that it causes severe side effects.

September 9th 2014

AACR's Policy Statement Urges FDA-Regulation of Laboratory-Developed Tests

The statement points to the increased complexity of some of the LDTs and highlights patient safety issues that are at stake.

September 9th 2014

DEA Moves to Curtail Drug Abuse

With the objective of reducing drug abuse, especially by teenagers, the D.E.A. will now allow patients and their relatives to mail-in their unneeded stockpiles of prescription drugs back to the pharmacies.

September 9th 2014

Global Study Identifies Prediabetes as a Risk Factor for Cancer

A meta-analysis comprising 16 studies and 891,426 participants from various regions of the world shows that prediabetes increases the risk of cancer by 15%, with differing risks depending on the type of cancer.

September 8th 2014

Genomic Analysis Determines Post-Surgery Treatment in Prostate Cancer

The results of the genomic data can guide treatment decisions post-surgery in prostate cancer.

September 5th 2014

Family History Alone May Not Tell the Tale in Jewish Women

Although family history is a risk factor, a new study has shown that it should not be the primary determinant of mutation screening for breast and ovarian cancer.

September 5th 2014

Smoke-Free Homes Now the Overwhelming Norm, Even in Tobacco States, CDC Reports

Mary K. Caffrey

Growing up in a smoke-free home is now the overwhelming norm for most Americans, with the share of smoke-free homes nearly doubling in the 20 years that ended in 2011, the Centers for Disease Control and Prevention said today in a new study. Overall, the prevalence of smoke-free home rules increased from 43 percent during 1992—1993 to 83 percent during 2010—2011, according to the study, which appears in today's Mortality and Morbidity Weekly Report, published by CDC.

September 5th 2014

Fee-For-Service May Introduce Treatment Bias in Radiation Oncology

The write believes that the episodic reimbursement model might introduce bias among radiation oncologists who own their own treatment equipment.

September 5th 2014

Effects of Multidisciplinary Team Care on Utilization of Emergency Care for Patients With Lung Cancer

Shun-Mu Wang, MHA Pei-Tseng Kung, ScD Yueh-Hsin Wang, MHA Kuang-Hua Huang, PhD Wen-Chen Tsai, DrPH

Impact of multidisciplinary team care on reducing utilization of emergency department visits for patients with lung cancer.

September 4th 2014

Perspective: The Value of Care and QALY

Does $50,000 per quality-adjusted life year (QALY) hold value in today's age of high-priced specialty drugs? The authors evaluate this yardstick and recommend changes that could aid cost-effectiveness decisions.

September 4th 2014

What Will Drive the Expected Rise in US Healthcare Spending?

Mary K. Caffrey

Yesterday's government report that healthcare spending will start rising faster after a decade of historically slow growth raises questions: Will rising numbers of insured people drive the spending? Or are healthcare costs going up on their own? The answer is likely some of each, based on a look at trends within yesterday's report and a just-released study of spending by commercial health plans, published in The American Journal of Managed Care.

September 4th 2014

Pembrolizumab Approved For Advanced Melanoma

Following a breakthrough therapy designation, pembrolizumab was included in FDA's accelerated approval program to allow early patient access.

September 4th 2014

Opdivo Reignites the Drug Pricing Discussion

While Sovaldi is still fresh on the mind, Ono Pharmaceutical's Opdivo (nivolumab), marketed jointly with BMS in Japan, has analysts projecting what the treatment might cost in the US.

September 3rd 2014

JAMA Study Does Not Find Improved Survival With Double Mastectomy

Survival at 10 years was no better when women had double mastectomies.

September 3rd 2014

ASCO Updates Clinical Guidelines for HER2-Negative Breast Cancer

The guidelines suggest various treatment options available, following consideration of the patient's status and preference.

...

153 154 155 156 157 158 159 160 161

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions